Spore.Bio announced it has appointed Dr. Michael J. Miller as Vice President of Scientific and Regulatory Affairs, adding a longtime industry specialist in rapid microbiological methods and contamination control as the company scales its manufacturing quality control platform.

Spore.Bio said Dr. Michael J. Miller brings nearly four decades of experience spanning pharmaceutical microbiology, contamination control, and validation of rapid microbiological methods, including senior and executive microbiology roles at Johnson & Johnson, Eli Lilly and Company, and Bausch & Lomb.

Michael Miller explained “Spore.Bio is tackling a problem I’ve spent my entire career thinking about: how to make microbiology faster, more reliable, and more actionable for manufacturers. The combination of AI, biophotonics, and microbiology Spore.Bio is building has the potential to redefine what ‘rapid methods’ mean. I’m excited to work with a firm that continues to set the standard for what a scientifically robust, validated and regulated platform can bring to users across pharma and beyond.”

In addition to corporate leadership roles, Spore.Bio noted that Dr. Michael J. Miller has served as an expert witness in pharmaceutical and medical device patent and product liability cases, advised the United States Pharmacopeia Microbiology Expert Committee, and authored more than 100 technical publications and presentations.

The company also highlighted his participation on editorial and scientific review boards for American Pharmaceutical Review, European Pharmaceutical Review, and PDA Journal of Pharmaceutical Science and Technology, as well as his consulting work advising multinational companies on microbiology, quality, and regulatory affairs.

Spore.Bio said Dr. Michael J. Miller is chairing the revision of Parenteral Drug Association Technical Report No. 33 and operates an educational platform focused on rapid microbiological methods. In his new role, the company expects him to help strengthen scientific positioning and regulatory engagement as it expands deployments of its on-site hardware and software stack.

Founded in 2023 by Amine Raji, Maxime Mistretta, and Mohamed Tazi, Spore.Bio combines photonics and AI to deliver real-time, high-precision contamination detection, modernizing microbiology testing in pharmaceuticals and other regulated industries.

“Bringing the biggest Key Opinion Leader of our field into Spore.Bio is a strong signal of where we’re headed as a company. His decades of experience in rapid methods, contamination control, and regulatory strategy give us exactly the kind of scientific and regulatory backbone we need as we scale and with Michael on board, we’re not just advancing our technology – we’re raising the bar for how it is validated, implemented and communicated to regulators, partners and customers. This is an important milestone for Spore.Bio, and it’s only the beginning of what we’ll be announcing in the weeks ahead.” said Amine Raji.

The company said the appointment comes ahead of a planned March 24 announcement at a Parenteral Drug Association conference in Denver and at the European Microbiology Jubilee Conference in Wiesbaden.

Spore.Bio also said it was awarded funding as part of Google.org’s inaugural AI for Science Forum and has raised €29.9 million to date from investors including Singular, LocalGlobe, Point72, and Famille C, the Clarins family office, among others.